Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Ryvu
company
About
Ryvu is a biopharmaceutical company developing small molecule therapies that address clinical limitations of current treatments in oncology.
- 101 - 250
Highlights
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- €20M
- Industries
- Biotechnology,Health Care,Medical,Pharmaceutical
- Founded date
- Jan 1, 2007
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Ryvu is a biopharmaceutical company developing small-molecule therapies that address the clinical limitations of current treatments in oncology.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
€42M
Ryvu has raised a total of
€42M
in funding over 2 rounds. Their latest funding was raised on
Nov 30, 2022 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 30, 2022 | Post-IPO Equity | €20M | 1 |
BioNTech
|
— | Detail |
| Aug 17, 2022 | Post-IPO Debt | €22M | 1 |
European Investment Bank
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
2
Ryvu is funded by 2 investors.
BioNTech
and European Investment Bank
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
BioNTech
|
Yes | Post-IPO Equity |
|
European Investment Bank
|
Yes | Post-IPO Debt |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
